MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$2.74 USD
-0.07 (-2.49%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.47 | -44.64 | 19.58 | -213.72 | -52.50 |
Depreciation/Amortization & Depletion | 0.57 | 0.90 | 0.88 | 2.05 | 2.01 |
Net Change from Assets/Liabilities | -1.59 | 2.25 | -2.54 | -4.38 | -9.79 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.36 | -6.52 | -25.13 | 179.66 | 1.63 |
Net Cash From Operating Activities | -21.13 | -48.02 | -7.20 | -36.39 | -58.65 |
Property & Equipment | 0.00 | -0.01 | -0.74 | -0.02 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | -0.45 | 12.86 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 41.97 |
Other Investing Activities | -0.42 | 1.86 | 0.16 | 2.39 | 0.48 |
Net Cash from Investing Activities | -0.42 | 1.85 | -0.58 | 1.92 | 55.28 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 11.61 | 0.00 | 108.05 | 25.85 | -1.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 31.55 | 0.00 |
Increase (Decrease) Short-Term Debt | -3.19 | 0.00 | -0.95 | -2.68 | -2.82 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.44 | 0.00 | -0.32 | -10.13 | -3.19 |
Net Cash from Financing Activities | 7.97 | -0.97 | 106.78 | 44.60 | -7.29 |
Effect of Exchange Rate Changes | 2.82 | 0.18 | -1.60 | -0.99 | -0.45 |
Net Change In Cash & Equivalents | -10.76 | -46.96 | 97.39 | 9.14 | -11.10 |
Cash at Beginning of Period | 68.18 | 116.63 | 32.27 | 20.99 | 31.98 |
Cash at End of Period | 57.42 | 69.68 | 129.67 | 30.13 | 20.87 |
Diluted Net EPS | -0.20 | -0.37 | -0.34 | -3.10 | -2.49 |
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -29.47 | NA | -14.95 | NA |
Depreciation/Amortization & Depletion | NA | 0.57 | NA | 0.33 | NA |
Net Change from Assets/Liabilities | NA | -1.59 | NA | -7.97 | NA |
Net Cash from Discontinued Operations | NA | 0.00 | NA | NA | NA |
Other Operating Activities | NA | 9.36 | NA | 5.98 | NA |
Net Cash From Operating Activities | NA | -21.13 | NA | -16.61 | NA |
Property & Equipment | NA | 0.00 | NA | NA | NA |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | NA | NA | NA |
Investments | NA | 0.00 | NA | NA | NA |
Other Investing Activities | NA | -0.42 | NA | 0.16 | NA |
Net Cash from Investing Activities | NA | -0.42 | NA | 0.16 | NA |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 11.61 | NA | 0.00 | NA |
Issuance (Repayment) of Debt | NA | 0.00 | NA | NA | NA |
Increase (Decrease) Short-Term Debt | NA | -3.19 | NA | -0.28 | NA |
Payment of Dividends & Other Distributions | NA | 0.00 | NA | NA | NA |
Other Financing Activities | NA | -0.44 | NA | -0.87 | NA |
Net Cash from Financing Activities | NA | 7.97 | NA | -1.15 | NA |
Effect of Exchange Rate Changes | NA | 2.82 | NA | -0.22 | NA |
Net Change In Cash & Equivalents | NA | -10.76 | NA | -17.81 | NA |
Cash at Beginning of Period | NA | 68.18 | NA | 70.54 | NA |
Cash at End of Period | NA | 57.42 | NA | 52.73 | NA |
Diluted Net EPS | NA | NA | NA | NA | NA |